Advertisement

Conclusions

  • A. E. Frankel
  • M. C. Willingham
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 234)

Abstract

The targeted toxin research reviewed in this volume includes recent advances in clinical applications of these compounds. The observation of clinical efficacy of both transferrin conjugated to mutant diphtheria toxin in high-grade gliomas and truncated diphtheria toxin fused to interleukin-2 in cutaneous T cell lymphomas and psoriasis are achievements for which all the members of the targeted toxin research community can be proud. The participation of so many colleagues in this field in this book has been a reflection both of the kindness and friendliness of the individuals as well as their commitment to working together to develop a new class of human therapeutics.

Keywords

Diphtheria Toxin Large Granular Lymphocyte Fusion Toxin Pokeweed Antiviral Protein Vascular Leak Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bookman M, Godfrey S, Padavic K, Griffin T, Corda J, Hamilton T, Ozols R, Groves E (1990) Antitransferrin receptor immunotoxin (IT) therapy: phase I intraperitoneal (i.p.) Trial. Proc Am Soc Clin Oncol 9: 187Google Scholar
  2. Capizzi RL (1996) Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23: 2–17PubMedGoogle Scholar
  3. Duvic M, Cather J, Maize J, Frankel AE (1997) DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Lancet (submitted)Google Scholar
  4. Falini B, Bolognesi A, Flenghi L, Tazzari P, Broe M, Stein H, Durkop H, Aversa F, Correli P, Pizzolo G, Barbabietola G, Sabattini E, Pileri S, Martelli M, Stirpe F (1992) Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 339: 1–5CrossRefGoogle Scholar
  5. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Gamier J, Niaudet P (1991) Anti-B cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324: 1451–1456PubMedCrossRefGoogle Scholar
  6. Frankel AE, Tagge EP, Willingham MC (1995) Clinical trials of targeted toxins. Semin Cancer Biol 6: 307–317PubMedCrossRefGoogle Scholar
  7. Frankel AE, Laver J, Willingham MC, Burns L, Kersey J, Vallera DA (1997) Therapy of patients with T-cell lymphomas using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymph (in press)Google Scholar
  8. Ghetie M, Tucker K, Richardson J, Uhr J, Vitetta E (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84: 702–707PubMedGoogle Scholar
  9. Gould B, Borowitz M, Groves E, Carter P, Anthony D, Weiner J, Frankel A (1989) A phase I study of a continuous infusion anti-breast cancer immunotoxin: report of a targeted toxicity not predicted by animal studies. JNCI 81: 774–781Google Scholar
  10. Grossbard M, Freedman A, Ritz J, Coral F, Goldmacher V, Eliseo L, Spector N, Dear K, Lambert J, Blattler W, Taylor J, Nadler L (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin. A phase I trial of daily bolus infusion. Blood 79: 576–582Google Scholar
  11. Holloway KB (1992) Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 27: 367–378PubMedCrossRefGoogle Scholar
  12. Jansen B, Kersey J, Jaszcz W, Gunther R, Nguyen D, Chelstrom L, Tuelahlgren L, Uckun F (1993) Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CDI9)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 7: 290–297PubMedGoogle Scholar
  13. Lidor Y, O’Briant K, Xu F, Hamilton T, Ozols R, Bast R (1993) Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. J Clin Invest 92: 2440–2447PubMedCrossRefGoogle Scholar
  14. Liu C, Lambert J, Teicher B, Blattler W, O’Connor R (1996) Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 87: 3892–3898PubMedGoogle Scholar
  15. Loughran TP (1993) Clonal diseases of large granular lymphocytes. Blood 82: 1–14PubMedGoogle Scholar
  16. O’Connor R, Liu C, Ferris C, Guild B, Teicher B, Corvi C, Liu Y, Arceci R, Goldmacher V, Lambert J, Blattler W (1995) Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrugresistant and drug-sensitive tumors. Blood 86: 4286–4294PubMedGoogle Scholar
  17. Pai L, Bookman M, Ozols R, Young R, Smith J, Longo D, Gould B, Frankel A, McClay E, Howell S, Reed E, Willingham M, FitzGerald D, Pastan I (1991) Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9: 2095–2102PubMedGoogle Scholar
  18. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I (1996) Treatment of advanced solid tumors with immunotoxin LMB-I: an antibody linked to Pseudomonas exotoxin. Nature Med 2: 350–353PubMedCrossRefGoogle Scholar
  19. Pastan 1H (1997) Tumor immunotoxins: technology closes in on potential. Adv Oncol 13: 3–9Google Scholar
  20. Pearson J, FitzGerald D, Willingham M, Wiltrout R, Pastan I, Longo D (1989a) Chemóinrmunotoxin therapy against a human colon tumor (HT-29) xenograft in nude mice. Cancer Res 49: 3562–3567PubMedGoogle Scholar
  21. Pearson J, Sivam G, Manger R, Wiltrout R, Morgan A, Longo D (1989b) Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res 49: 4990–4995PubMedGoogle Scholar
  22. Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe ES, Sausville EA (1997) Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med 126: 882–885PubMedGoogle Scholar
  23. Soler-Rodriguez A, Ghetie M, Oppenheimer-Marks N, Uhr J, Vitetta E (1993) Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 206: 227–234PubMedCrossRefGoogle Scholar
  24. Strom T, Kelley V, Murphy J, Nichols B, Woodworth T (1994) Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Adv Nephrol 23: 347–356Google Scholar
  25. Uckun FM (1993) Immunotoxins for the treatment of leukaemia. Br J Haematol 85: 435–438PubMedCrossRefGoogle Scholar
  26. Uckun F, Gajl-Peczalska K, Myers D, Ramsay N, Kersey J, Colvin M, Vallera D (1987) Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxy-cyclophosphamide against fresh leukemic marrow progenitor cells. Blood 69: 361–366PubMedGoogle Scholar
  27. Weil-Hillman G, Uckun F, Manske J, Vallera D (1987) Combined immunochemotherapy of human solid tumors in nude mice. Cancer Res 47: 579–585PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • A. E. Frankel
    • 1
  • M. C. Willingham
    • 1
  1. 1.Hollings Cancer CenterCharlestonUSA

Personalised recommendations